Loxo Oncology Inc (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 15,000 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $96.57, for a total transaction of $1,448,550.00. Following the transaction, the chief executive officer now owns 190,207 shares in the company, valued at approximately $18,368,289.99. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of Loxo Oncology Inc (LOXO) traded up $3.43 on Thursday, reaching $104.35. 504,000 shares of the company traded hands, compared to its average volume of 335,555. The company has a market cap of $3,120.00, a P/E ratio of -17.96 and a beta of 2.56. Loxo Oncology Inc has a 12-month low of $40.01 and a 12-month high of $108.50.
A number of research analysts have recently weighed in on LOXO shares. Citigroup cut their price target on shares of Loxo Oncology from $112.00 to $108.00 and set a “buy” rating on the stock in a report on Thursday, November 16th. BidaskClub upgraded shares of Loxo Oncology from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Zacks Investment Research upgraded shares of Loxo Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. William Blair started coverage on shares of Loxo Oncology in a report on Tuesday, November 28th. They set an “outperform” rating on the stock. Finally, JMP Securities upgraded shares of Loxo Oncology from a “market perform” rating to an “outperform” rating and raised their price target for the company from $77.18 to $95.00 in a report on Tuesday, November 14th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Loxo Oncology has a consensus rating of “Buy” and an average target price of $97.33.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.